A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer (Q46138064)

19 December 2017

title

A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer (English)

1 reference

19 December 2017

main subject

phase I clinical trial

0 references

1 reference

Andrew H Ko

1

1 reference

19 December 2017

Thach-Giao Truong

2

1 reference

19 December 2017

Emily Kantoff

3

1 reference

19 December 2017

Kimberly A Jones

4

1 reference

19 December 2017

Elizabeth Dito

5

1 reference

19 December 2017

Anna Ong

6

1 reference

19 December 2017

Margaret A Tempero

7

1 reference

19 December 2017

publication date

28 September 2012

1 reference

19 December 2017

Cancer Chemotherapy and Pharmacology

published in

1 reference

19 December 2017

volume

70

1 reference

19 December 2017

issue

6

1 reference

19 December 2017

page(s)

875-881

1 reference

19 December 2017

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1979-7

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1979-7

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1979-7

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1979-7

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1979-7

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1979-7

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1979-7

The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1979-7

Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1979-7

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1979-7

nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1979-7

Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1979-7

Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1979-7

Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1979-7

Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1979-7

Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1979-7

A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1979-7

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1979-7

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1979-7

10.1007/S00280-012-1979-7

21 January 2018

Identifiers

DOI

1 reference

19 December 2017

1 reference

19 December 2017